Currently browsing tag

valeant

Valeant gets notice of default from bondholders

(Reuters) – Beleaguered Canadian drugmaker Valeant Pharmaceuticals International Inc said it received a notice of default from bondholders for the delay in filing its first-quarter report. Last week, Valeant had said it expected to file the report with U.S. and Canadian regulators on or before June 10, ahead of a July 31 deadline. Valeant had been one of the pharmaceutical industry's most widely owned stocks as its steady stream of acquisitions fueled strong gains in its shares.

Valeant says CEO J. Michael Pearson hospitalized with severe pneumonia

Valeant Pharmaceuticals International Inc Chief Executive J. Michael Pearson was hospitalized with a “severe case of pneumonia” on Friday and is receiving treatment, a company spokeswoman said. Pearson, 56, joined Valeant as CEO in September 2010 after a 23-year career at McKinsey & Company and became chairman of the board in 2010. Under Pearson's leadership, the company has come under U.S. government scrutiny for acquiring off-patent drugs and drastically hiking the prices.